drugset / Trial / NCT00731861

Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors

NCT00731861

Phase 1 Completed 28 enrolled Indiana University Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate PTK787, a new oral drug that stops blood vessel development, in combination with Paclitaxel in patients with advanced solid tumors.

Timeline

Start
2005-05
Primary completion
2008-09
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject vatalanib Small molecule Oral
Background Paclitaxel Small molecule